Specialty Pharmacy

Co-administration of amiodarone and Sovaldi or Harvoni also causes 9 patients to develop abnormally slow heartbeats, 3 requiring pacemakers.

Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses adherence trends specialty pharmacies need to be aware of.

Procedure allows acute liver failure patients to receive a transplant before their condition worsens.

Emerging technology could help patients make better decisions regarding whether to undergo aggressive prostate cancer treatment.

A look back at some of the top stories on Specialty Pharmacy Times from March 16-20.

Communication helps pharmacists better assess difficulties patients encounter during treatment.

A health-system pharmacist was recently let go after peeking at the health records of patients not in his care.

Condition shares pathogenic mechanisms with rheumatoid arthritis.

Acquisition creates most integrated pharmacy technology company in the industry.

Significant number of patients taking once daily oral therapy achieve clinical remission during a recent trial.

Discovery may lead to new treatment designs.

Experimental treatment blocks signaling protein.

Genetic variations on chromosome 15 dictate impact of NSAIDs.

A pharmacist involved in a Medicare scheme has pleaded guilty to health care fraud.

Process produces protein with high blood clotting ability.

Globally, from Tunisia to the United States, underuse of digital temperature loggers leads to loss of product potency and efficacy for patients.

As the US Centers for Medicare and Medicaid Services places a greater emphasis on medication adherence through its star ratings, pharmacists and other health care professionals continue to seek ways to improve adherence among seniors.

Risk of sudden onset menopause reduced by adding goserelin to chemotherapy regimen.

Patients with bile acid synthesis and peroxisomal disorders will soon have access to the first FDA-approved treatment option.

A drug typically used to treat herpes may reduce HIV-1 levels, even in those who don't have herpes.

The agency is slated to review the new drug application within a 6-month timeframe.

Report finds suppliers could spur investment through methods that include equipment leases or supplier-financed credit.

Treatment can selectively drop medication at the site of tumors.

Raulo Frear, PharmD, general manager of OmedaRx, discusses the services his company offers.

Historical comparison shows advantage in virologic response for patients with genotype 1 hepatitis C.

Survivors of breast cancer more likely to develop aggressive form of thyroid cancer.

More than 90% of HIV transmissions originate from undiagnosed and untreated individuals. On the other hand, those retained in medical care who have achieved viral suppression are 94% less likely to transmit HIV.

Study finds older patients and minorities less likely to receive treatment.